AR019388A1 - (3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion. - Google Patents

(3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion.

Info

Publication number
AR019388A1
AR019388A1 ARP990103446A ARP990103446A AR019388A1 AR 019388 A1 AR019388 A1 AR 019388A1 AR P990103446 A ARP990103446 A AR P990103446A AR P990103446 A ARP990103446 A AR P990103446A AR 019388 A1 AR019388 A1 AR 019388A1
Authority
AR
Argentina
Prior art keywords
tetrahydro
amino
compositions
processes
preparation
Prior art date
Application number
ARP990103446A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR019388A1 publication Critical patent/AR019388A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe el (3S)tetrahidro-3-furanil(1S), 2R)-3-[[(4-aminofenil)sulfonil]-(isobutil)amino]-1-bencil-2-(fosfooxi) propilcarbamato de calcio, procesospara su uso en el tratamiento de enfermedades causadas por retrovirus, composiciones y procesopara su preparacion. formula (1)
ARP990103446A 1998-07-18 1999-07-14 (3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion. AR019388A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
AR019388A1 true AR019388A1 (es) 2002-02-13

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103446A AR019388A1 (es) 1998-07-18 1999-07-14 (3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion.

Country Status (47)

Country Link
US (3) US6514953B1 (es)
EP (2) EP1098898B1 (es)
JP (1) JP3437553B2 (es)
KR (1) KR100694721B1 (es)
CN (1) CN1188422C (es)
AP (1) AP2001002039A0 (es)
AR (1) AR019388A1 (es)
AT (1) ATE229964T1 (es)
AU (1) AU766056B2 (es)
BG (1) BG105253A (es)
BR (1) BRPI9912156B8 (es)
CA (1) CA2337857C (es)
CO (1) CO5090836A1 (es)
CZ (1) CZ300447B6 (es)
DE (1) DE69904600T2 (es)
DK (1) DK1098898T3 (es)
DZ (1) DZ2845A1 (es)
EA (1) EA003191B1 (es)
EE (1) EE200100038A (es)
ES (1) ES2189450T3 (es)
GB (1) GB9815567D0 (es)
GC (1) GC0000105A (es)
GE (1) GEP20033030B (es)
GT (1) GT199900111A (es)
HR (1) HRP20010046A2 (es)
HU (1) HU229700B1 (es)
ID (1) ID28070A (es)
IL (1) IL140824A (es)
IS (1) IS5808A (es)
JO (1) JO2114B1 (es)
MA (1) MA26660A1 (es)
MY (1) MY122323A (es)
NO (1) NO329676B1 (es)
NZ (1) NZ509291A (es)
OA (1) OA11706A (es)
PA (1) PA8477801A1 (es)
PE (1) PE20000869A1 (es)
PL (1) PL195736B1 (es)
PT (1) PT1098898E (es)
SK (1) SK285311B6 (es)
SV (1) SV1999000096A (es)
TN (1) TNSN99145A1 (es)
TR (1) TR200100111T2 (es)
TW (1) TWI245770B (es)
WO (1) WO2000004033A1 (es)
YU (1) YU3401A (es)
ZA (1) ZA200100417B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
OA12053A (en) * 1999-10-06 2006-05-02 Tibotec Pharm Ltd HexahydrofuroÄ2,3-bÜfuran-3-yl-N-ä3-Ä(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)aminoÜ-1-benzyl-2-hydroxypropylücarbamate as retroviral protease inhibitor.
ECSP003699A (es) * 1999-10-08 2002-04-23 Smithkline Beecham Corp Inhibidores de fab i
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
WO2003090691A2 (en) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
EP1575951B1 (en) 2002-12-06 2014-06-25 Debiopharm International SA Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
PT1670448E (pt) * 2003-09-30 2008-02-11 Tibotec Pharm Ltd Sulfonamidas inibidoras de hcv
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7273717B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
JP2007515495A (ja) 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物
US8450307B2 (en) 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
PL1824563T3 (pl) 2004-11-26 2010-07-30 Ucl Business Plc Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
WO2008112289A2 (en) 2007-03-12 2008-09-18 Nektar Therapeutics Oligomer-protease inhibitor conjugates
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
SG174982A1 (en) 2009-04-03 2011-11-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
JP5749255B2 (ja) 2009-06-08 2015-07-15 ユーシーエル ビジネス ピーエルシー Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
US20120208787A1 (en) * 2009-06-30 2012-08-16 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
US9085592B2 (en) 2009-09-16 2015-07-21 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
EP2507250A1 (en) * 2010-01-07 2012-10-10 Pliva Hrvastka D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
WO2011158259A1 (en) * 2010-06-18 2011-12-22 Matrix Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
JP2014513044A (ja) * 2011-02-10 2014-05-29 マイラン ラボラトリーズ リミテッド ホスアンプレナビルカルシウム結晶およびその調製方法
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
WO2013105118A1 (en) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
KR101720885B1 (ko) 2012-06-19 2017-03-28 데비오팜 인터네셔날 에스 에이 (e)-n-메틸-n-((3-메틸벤조푸란-2-일)메틸)-3-(7-옥소-5,6,7,8-테트라히드로-1,8-나프티리딘-3-일)아크릴아미드의전구약물 유도체
IL281349B (en) 2014-11-24 2022-09-01 Ucl Business Ltd Treatment of diseases related to hepatic stellate cell activity using ammonia-lowering treatments
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
RS61312B1 (sr) 2016-02-26 2021-02-26 Debiopharm Int Sa Lek za lečenje infekcija dijabetskog stopala
CA3063134A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
MY203711A (en) 2019-02-14 2024-07-15 Debiopharm Int Sa Afabicin formulation, method for making the same and uses thereof
JP7418475B2 (ja) 2019-06-14 2024-01-19 デバイオファーム インターナショナル エス．エー． バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AP2000001856A0 (en) * 1997-12-24 2000-09-30 Vertex Pharma Prodrugs of aspartyl protease inhibitors.
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
CN1154491C (zh) * 1998-11-04 2004-06-23 法玛西雅厄普约翰美国公司 用于改善替普拉那维的药物动力学的方法
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
AU777824B2 (en) * 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors

Also Published As

Publication number Publication date
BRPI9912156B1 (pt) 2016-07-26
AU5037999A (en) 2000-02-07
IL140824A0 (en) 2002-02-10
ID28070A (id) 2001-05-03
DZ2845A1 (fr) 2003-12-01
GC0000105A (en) 2005-06-29
US20030100537A1 (en) 2003-05-29
PL345620A1 (en) 2002-01-02
HK1034261A1 (en) 2001-10-19
AP2001002039A0 (en) 2001-03-31
EA003191B1 (ru) 2003-02-27
HUP0103432A2 (hu) 2002-04-29
GT199900111A (es) 2001-01-05
AU766056B2 (en) 2003-10-09
CZ300447B6 (cs) 2009-05-20
NZ509291A (en) 2003-05-30
EP1240903A2 (en) 2002-09-18
DE69904600D1 (de) 2003-01-30
CZ2001219A3 (cs) 2001-07-11
CN1324363A (zh) 2001-11-28
DE69904600T2 (de) 2003-11-13
PL195736B1 (pl) 2007-10-31
MA26660A1 (fr) 2004-12-20
PA8477801A1 (es) 2000-05-24
SK762001A3 (en) 2001-10-08
MY122323A (en) 2006-04-29
BR9912156A (pt) 2001-04-10
PE20000869A1 (es) 2000-09-08
CN1188422C (zh) 2005-02-09
PT1098898E (pt) 2003-04-30
GB9815567D0 (en) 1998-09-16
OA11706A (en) 2005-01-13
NO20010282D0 (no) 2001-01-17
TNSN99145A1 (fr) 2005-11-10
IL140824A (en) 2004-09-27
BG105253A (en) 2001-12-29
DK1098898T3 (da) 2003-04-07
KR100694721B1 (ko) 2007-03-15
US20030096795A1 (en) 2003-05-22
BRPI9912156B8 (pt) 2021-05-25
HU229700B1 (en) 2014-05-28
CA2337857A1 (en) 2000-01-27
CA2337857C (en) 2011-01-25
HRP20010046A2 (en) 2002-02-28
ATE229964T1 (de) 2003-01-15
JO2114B1 (en) 2000-05-21
ES2189450T3 (es) 2003-07-01
CO5090836A1 (es) 2001-10-30
US6514953B1 (en) 2003-02-04
JP3437553B2 (ja) 2003-08-18
EE200100038A (et) 2002-06-17
ZA200100417B (en) 2002-02-27
EP1098898A1 (en) 2001-05-16
TWI245770B (en) 2005-12-21
GEP20033030B (en) 2003-07-25
IS5808A (is) 2001-01-12
JP2003521447A (ja) 2003-07-15
EP1240903A3 (en) 2003-02-12
EA200100053A1 (ru) 2001-08-27
HUP0103432A3 (en) 2003-01-28
EP1098898B1 (en) 2002-12-18
KR20010071952A (ko) 2001-07-31
YU3401A (sh) 2005-06-10
SK285311B6 (sk) 2006-10-05
SV1999000096A (es) 2000-07-06
WO2000004033A1 (en) 2000-01-27
NO20010282L (no) 2001-03-07
NO329676B1 (no) 2010-11-29
TR200100111T2 (tr) 2002-02-21

Similar Documents

Publication Publication Date Title
AR019388A1 (es) (3s) tetrahidro-3-furanil (1s, 2r)-3-[[(4-aminofenil)sulfonil)](isobutil)amino]-1-bencil-2-(fosfonooxi)propilcarbamato de calcio y composiciones del mismo,su uso en el tratamiento de infecciones retrovirales y procesos para su preparacion.
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
PT96068A (pt) Processo para a producao de proteina biologicamente activa
SE9802729D0 (sv) Novel Compounds
AU2003217055A1 (en) Protein for use in hypoxia related conditions
BR0210941A (pt) Terapia de combinação de oxazolidinonas substituìdas
ES2063278T3 (es) Proteina morfogenetica de hueso.
BR9808938A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
ATE337316T1 (de) Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
NL960024I2 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus besmette patiënten.
PT100914A (pt) Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
BR0211635A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um indivìduo sofrendo de ou propenso à doença de alzheimer
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ES2195000T3 (es) Composicion farmaceutica.
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
WO2001000635A3 (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
PT972521E (pt) Composicao farmaceutica contendo estimuladores de interferao gama
DE60003074D1 (de) Fusidinsäure-derivate
ECSP993057A (es) Tetrahidro -3-furanil (1s,2r)-3-[[(4-aminofenil] sulfonil)] (isobutil) amino] -1- bencil-2 - (fosfonooxi) propilcarbamato de calcio
BR0109345A (pt) Compostos com atividade anti-hiv

Legal Events

Date Code Title Description
FC Refusal